Literature DB >> 1354540

Effects of peptidase inhibition on angiotensin receptor agonist and antagonist potency in rabbit isolated thoracic aorta.

M J Robertson1, M P Cunoosamy, K L Clark.   

Abstract

1. Experiments were performed with peptidase inhibitors on rabbit aortic strip preparations, to determine whether endogenous peptidase activity can influence the potency estimates for angiotensin receptor agonists and antagonists in this tissue. 2. Angiotensin II (A II) and angiotensin III (A III) both induced concentration-related contractions of rabbit aortic strip preparations. A III was approximately 38 fold less potent than A II, and the gradient of the A III concentration-response curve (1.00 +/- 0.04) was significantly more shallow than that (1.76 +/- 0.05) of the A II curve. 3. Neither the aminopeptidase-A and -M inhibitor, amastatin, nor the aminopeptidase-B and -M inhibitor, bestatin, affected the potency of, or the maximum response to, A II. In contrast, the potency of A III was increased by both amastatin and bestatin. Amastatin had the most marked effect and at 10 microM caused approximately a 12 fold increase in the potency of A III (EC50 values, 102 nM and 8.6 nM in the absence and presence of amastatin, respectively), and also significantly steepened the gradient of the A III concentration-response curve. Amastatin did not affect the position or shape of the concentration-response curve to the alpha 1-adrenoceptor agonist, phenylephrine. Finally, the carboxypeptidase-N inhibitor, D-L-mercaptomethyl-3-guanidine-ethylpropanoic acid (MERGETPA) did not change the position or shape of the concentration-response curves to either A II or A III.4. In the presence of amastatin, the potency of the peptide angiotensin receptor antagonist, Ile7-A III (100nM-l microM ), was increased approximately 13 fold (pA2, with A II as the agonist, 7.0 +/- 0.1 and 8.1 +/- 0.1, in the absence and presence of amastatin, respectively). However, the potency of the nonpeptide angiotensin receptor antagonist, DuP 753 (30-300 nM), was little affected by amastatin (pA2, 8.2 +/- 0.1 and 8.1 +/- 0.1 in the absence and presence of amastatin, respectively).5. The results of this study suggest that endogenous aminopeptidase activity in the rabbit thoracic aorta can profoundly affect estimates of the potency of peptide angiotensin receptor agonists and antagonists.A suitable aminopeptidase inhibitor should therefore be included in studies, using this tissue, which aim to classify angiotensin receptor subtype(s) based on the rank order of peptide angiotensin receptor agonist and/or antagonist potencies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354540      PMCID: PMC1907467          DOI: 10.1111/j.1476-5381.1992.tb14310.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  25 in total

Review 1.  Nonpeptide angiotensin II receptor antagonists.

Authors:  P B Timmermans; P C Wong; A T Chiu; W F Herblin
Journal:  Trends Pharmacol Sci       Date:  1991-02       Impact factor: 14.819

Review 2.  Renin-angiotensin system: biochemistry and mechanisms of action.

Authors:  M J Peach
Journal:  Physiol Rev       Date:  1977-04       Impact factor: 37.312

Review 3.  The renin-angiotensin system.

Authors:  I A Reid; B J Morris; W F Ganong
Journal:  Annu Rev Physiol       Date:  1978       Impact factor: 19.318

4.  Myotropic affinities of angiotensin II and des-AspI-angiotensin II in rabbit aorta and femoral artery by microassay.

Authors:  W H Waugh; T E Bales
Journal:  Can J Physiol Pharmacol       Date:  1979-11       Impact factor: 2.273

5.  A potent noncompetitive angiotensin II antagonist induces only competitive inhibition of angiotensin III responses.

Authors:  G J Trachte; M J Peach
Journal:  J Cardiovasc Pharmacol       Date:  1983 Nov-Dec       Impact factor: 3.105

6.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

7.  Metabolism of angiotensin II and some analogs in intact strips and in muscle preparations of rabbit aortae.

Authors:  J Magnan; D Regoli
Journal:  Can J Physiol Pharmacol       Date:  1978-02       Impact factor: 2.273

8.  Prejunctional nicotinic receptors involved in facilitation of stimulation-evoked noradrenaline release from the vas deferens of the guinea-pig.

Authors:  L Todorov; K Windisch; H Shersen; A Lajtha; M Papasova; E S Vizi
Journal:  Br J Pharmacol       Date:  1991-01       Impact factor: 8.739

9.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

10.  Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins.

Authors:  S Ahmad; P E Ward
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

View more
  7 in total

1.  Effects of angiotensin I and angiotensin II in blood vessels: greater influence of converting enzyme activity in the rabbit basilar artery.

Authors:  A Zerrouk; M Auguet; S Delaflotte; P E Chabrier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

2.  Angiotensin II and III metabolism and effects on steroid production in the HAC15 human adrenocortical cell line.

Authors:  Kenji Oki; Phillip G Kopf; William B Campbell; Milay Luis Lam; Takeshi Yamazaki; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez
Journal:  Endocrinology       Date:  2012-12-07       Impact factor: 4.736

3.  Pharmacological characterization of the contractile responses to angiotensin analogues in guinea-pig isolated longitudinal muscle of small intestine.

Authors:  A B Hawcock; J C Barnes
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

4.  Direct positive chronotropic effects of angiotensin II and angiotensin III in pithed rats and in rat isolated atria.

Authors:  Q Li; J Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist.

Authors:  M J Robertson; J C Barnes; G M Drew; K L Clark; F H Marshall; A Michel; D Middlemiss; B C Ross; D Scopes; M D Dowle
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

6.  Comparative effects of angiotensin II and its degradation products angiotensin III and angiotensin IV in rat aorta.

Authors:  Q Li; L Zhang; M Pfaffendorf; P A van Zwieten
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

Review 7.  Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects.

Authors:  Brigitte Bauvois; Daniel Dauzonne
Journal:  Med Res Rev       Date:  2006-01       Impact factor: 12.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.